Concepts (189)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antibodies, Neutralizing | 24 | 2025 | 303 | 4.110 |
Why?
|
| HIV Antibodies | 15 | 2021 | 247 | 2.770 |
Why?
|
| Antibodies, Viral | 10 | 2025 | 284 | 2.170 |
Why?
|
| Spike Glycoprotein, Coronavirus | 13 | 2025 | 101 | 2.070 |
Why?
|
| HIV-1 | 16 | 2024 | 1260 | 1.790 |
Why?
|
| Neutralization Tests | 11 | 2024 | 108 | 1.140 |
Why?
|
| Humans | 57 | 2025 | 14537 | 1.050 |
Why?
|
| HIV Infections | 20 | 2024 | 5097 | 0.900 |
Why?
|
| Epitopes | 8 | 2021 | 97 | 0.890 |
Why?
|
| Immune Evasion | 6 | 2022 | 31 | 0.860 |
Why?
|
| AIDS Vaccines | 9 | 2021 | 152 | 0.860 |
Why?
|
| HIV Envelope Protein gp120 | 6 | 2018 | 104 | 0.850 |
Why?
|
| Superinfection | 2 | 2018 | 8 | 0.670 |
Why?
|
| Mutation | 8 | 2024 | 306 | 0.610 |
Why?
|
| RNA, Viral | 2 | 2018 | 303 | 0.600 |
Why?
|
| Cross Reactions | 4 | 2024 | 44 | 0.600 |
Why?
|
| B-Lymphocytes | 6 | 2021 | 34 | 0.580 |
Why?
|
| Peptide Fragments | 2 | 2018 | 37 | 0.540 |
Why?
|
| Respiratory Syncytial Virus, Human | 3 | 2024 | 155 | 0.540 |
Why?
|
| Phylogeny | 5 | 2024 | 231 | 0.540 |
Why?
|
| South Africa | 21 | 2025 | 7596 | 0.500 |
Why?
|
| Pandemics | 5 | 2023 | 296 | 0.460 |
Why?
|
| Animals | 10 | 2024 | 1081 | 0.440 |
Why?
|
| Seroepidemiologic Studies | 5 | 2025 | 109 | 0.430 |
Why?
|
| Genome, Viral | 5 | 2024 | 64 | 0.400 |
Why?
|
| Immunity, Humoral | 2 | 2024 | 42 | 0.400 |
Why?
|
| Epidemiological Monitoring | 2 | 2022 | 45 | 0.390 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 2024 | 36 | 0.380 |
Why?
|
| Adult | 13 | 2025 | 5913 | 0.380 |
Why?
|
| Adjuvants, Immunologic | 2 | 2021 | 23 | 0.360 |
Why?
|
| Antibody Formation | 2 | 2021 | 61 | 0.350 |
Why?
|
| Middle Aged | 9 | 2025 | 3601 | 0.350 |
Why?
|
| Hospitalization | 3 | 2022 | 418 | 0.350 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 3 | 2021 | 52 | 0.350 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2024 | 200 | 0.340 |
Why?
|
| Female | 14 | 2025 | 9103 | 0.330 |
Why?
|
| Evolution, Molecular | 4 | 2024 | 60 | 0.330 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 142 | 0.300 |
Why?
|
| Laboratories | 2 | 2024 | 47 | 0.280 |
Why?
|
| Genomics | 3 | 2023 | 109 | 0.280 |
Why?
|
| Aged | 4 | 2025 | 1740 | 0.270 |
Why?
|
| Nanoparticles | 3 | 2021 | 104 | 0.240 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 65 | 0.240 |
Why?
|
| Phylogeography | 2 | 2021 | 15 | 0.230 |
Why?
|
| Adolescent | 4 | 2025 | 2985 | 0.230 |
Why?
|
| Male | 7 | 2025 | 6754 | 0.230 |
Why?
|
| Signal Transduction | 1 | 2024 | 33 | 0.230 |
Why?
|
| Receptors, IgG | 1 | 2024 | 28 | 0.230 |
Why?
|
| Severity of Illness Index | 2 | 2022 | 253 | 0.220 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2024 | 48 | 0.220 |
Why?
|
| Protein Engineering | 2 | 2020 | 7 | 0.220 |
Why?
|
| Intention | 1 | 2023 | 23 | 0.210 |
Why?
|
| Genetic Variation | 3 | 2024 | 175 | 0.210 |
Why?
|
| Peptides | 2 | 2020 | 40 | 0.210 |
Why?
|
| Models, Molecular | 5 | 2022 | 84 | 0.210 |
Why?
|
| Immunization | 2 | 2020 | 63 | 0.210 |
Why?
|
| Young Adult | 3 | 2025 | 2498 | 0.210 |
Why?
|
| Viruses | 1 | 2023 | 47 | 0.210 |
Why?
|
| Prospective Studies | 5 | 2024 | 1160 | 0.200 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2021 | 151 | 0.200 |
Why?
|
| Lymph | 1 | 2021 | 1 | 0.200 |
Why?
|
| Saponins | 1 | 2021 | 1 | 0.200 |
Why?
|
| Toll-Like Receptors | 1 | 2021 | 1 | 0.200 |
Why?
|
| Immunity, Cellular | 1 | 2022 | 25 | 0.200 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 4 | 0.200 |
Why?
|
| Terminology as Topic | 1 | 2021 | 11 | 0.190 |
Why?
|
| Hospital Mortality | 1 | 2021 | 95 | 0.180 |
Why?
|
| Plants, Genetically Modified | 1 | 2020 | 3 | 0.170 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2021 | 103 | 0.170 |
Why?
|
| Sequence Analysis, RNA | 2 | 2021 | 17 | 0.170 |
Why?
|
| Aluminum Hydroxide | 1 | 2020 | 1 | 0.170 |
Why?
|
| Tobacco | 1 | 2020 | 14 | 0.170 |
Why?
|
| Macaca mulatta | 4 | 2021 | 14 | 0.170 |
Why?
|
| Germinal Center | 1 | 2019 | 3 | 0.170 |
Why?
|
| Amino Acid Sequence | 5 | 2019 | 139 | 0.160 |
Why?
|
| Influenza Vaccines | 1 | 2021 | 144 | 0.160 |
Why?
|
| HIV | 3 | 2023 | 380 | 0.160 |
Why?
|
| Lysine | 1 | 2018 | 5 | 0.160 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2018 | 9 | 0.160 |
Why?
|
| Introns | 1 | 2018 | 13 | 0.160 |
Why?
|
| Exons | 1 | 2018 | 17 | 0.160 |
Why?
|
| World Health Organization | 3 | 2024 | 137 | 0.150 |
Why?
|
| Vaccines | 1 | 2019 | 86 | 0.150 |
Why?
|
| Influenza, Human | 1 | 2021 | 374 | 0.140 |
Why?
|
| Binding Sites, Antibody | 1 | 2017 | 8 | 0.140 |
Why?
|
| HIV Antigens | 1 | 2017 | 26 | 0.140 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2017 | 28 | 0.140 |
Why?
|
| Africa | 3 | 2022 | 376 | 0.130 |
Why?
|
| Antigenic Variation | 1 | 2015 | 7 | 0.130 |
Why?
|
| Molecular Sequence Data | 4 | 2015 | 263 | 0.110 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 1422 | 0.110 |
Why?
|
| HIV Envelope Protein gp160 | 1 | 2014 | 22 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2024 | 967 | 0.110 |
Why?
|
| Epitope Mapping | 3 | 2019 | 32 | 0.100 |
Why?
|
| Polysaccharides | 1 | 2012 | 45 | 0.100 |
Why?
|
| Child | 3 | 2022 | 2242 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 2 | 2021 | 11 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 12 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2022 | 272 | 0.090 |
Why?
|
| CD4 Antigens | 3 | 2017 | 49 | 0.090 |
Why?
|
| Glycosylation | 2 | 2021 | 17 | 0.080 |
Why?
|
| Lymphocyte Activation | 2 | 2020 | 40 | 0.080 |
Why?
|
| Vaccination | 2 | 2023 | 365 | 0.080 |
Why?
|
| Antibody Affinity | 2 | 2018 | 11 | 0.070 |
Why?
|
| Complementarity Determining Regions | 2 | 2017 | 11 | 0.060 |
Why?
|
| Antigens, Viral | 1 | 2024 | 21 | 0.060 |
Why?
|
| Bayes Theorem | 1 | 2024 | 81 | 0.060 |
Why?
|
| Immunocompromised Host | 1 | 2024 | 34 | 0.060 |
Why?
|
| HIV Seropositivity | 2 | 2019 | 265 | 0.060 |
Why?
|
| Antibody Specificity | 2 | 2013 | 30 | 0.050 |
Why?
|
| Australia | 1 | 2023 | 48 | 0.050 |
Why?
|
| United States | 1 | 2023 | 132 | 0.050 |
Why?
|
| Amino Acids | 1 | 2022 | 16 | 0.050 |
Why?
|
| Placebo Effect | 1 | 2022 | 1 | 0.050 |
Why?
|
| Convalescence | 1 | 2022 | 2 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2022 | 89 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2024 | 656 | 0.050 |
Why?
|
| Information Storage and Retrieval | 1 | 2022 | 13 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2022 | 17 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 26 | 0.050 |
Why?
|
| Botswana | 1 | 2022 | 24 | 0.050 |
Why?
|
| Rats, Wistar | 1 | 2021 | 13 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2022 | 46 | 0.050 |
Why?
|
| Recombination, Genetic | 1 | 2022 | 27 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2022 | 106 | 0.050 |
Why?
|
| Cryoelectron Microscopy | 1 | 2021 | 2 | 0.050 |
Why?
|
| Hospitals, Public | 1 | 2022 | 45 | 0.050 |
Why?
|
| Cell Line | 1 | 2021 | 93 | 0.050 |
Why?
|
| Rats | 1 | 2021 | 130 | 0.050 |
Why?
|
| Protein Conformation | 1 | 2021 | 24 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2022 | 133 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2022 | 171 | 0.050 |
Why?
|
| Mice | 1 | 2021 | 135 | 0.050 |
Why?
|
| Genetic Fitness | 1 | 2021 | 7 | 0.050 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2022 | 59 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 34 | 0.050 |
Why?
|
| Vaccine Potency | 1 | 2021 | 16 | 0.050 |
Why?
|
| Selection, Genetic | 1 | 2021 | 31 | 0.050 |
Why?
|
| Blood Donors | 1 | 2021 | 19 | 0.050 |
Why?
|
| Molecular Typing | 1 | 2021 | 12 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2021 | 15 | 0.050 |
Why?
|
| Logistic Models | 1 | 2022 | 254 | 0.050 |
Why?
|
| Communication | 1 | 2021 | 57 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 256 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2021 | 39 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 44 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2023 | 262 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 175 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 90 | 0.040 |
Why?
|
| Learning | 1 | 2020 | 12 | 0.040 |
Why?
|
| Biotechnology | 1 | 2020 | 4 | 0.040 |
Why?
|
| Genetic Engineering | 1 | 2020 | 7 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2020 | 10 | 0.040 |
Why?
|
| Phosphoserine | 1 | 2020 | 1 | 0.040 |
Why?
|
| Antigen Presentation | 1 | 2020 | 6 | 0.040 |
Why?
|
| Antigens | 1 | 2020 | 11 | 0.040 |
Why?
|
| Endocytosis | 1 | 2020 | 6 | 0.040 |
Why?
|
| Global Health | 1 | 2021 | 193 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2020 | 13 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2020 | 15 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2019 | 5 | 0.040 |
Why?
|
| Incidence | 1 | 2022 | 685 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2019 | 24 | 0.040 |
Why?
|
| Time Factors | 1 | 2021 | 507 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2022 | 889 | 0.040 |
Why?
|
| Protein Binding | 1 | 2018 | 62 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2018 | 17 | 0.040 |
Why?
|
| Prevalence | 1 | 2022 | 1192 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2018 | 39 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 45 | 0.040 |
Why?
|
| Alleles | 1 | 2018 | 143 | 0.040 |
Why?
|
| Tenofovir | 1 | 2018 | 171 | 0.040 |
Why?
|
| Rural Population | 1 | 2021 | 654 | 0.040 |
Why?
|
| Crystallography, X-Ray | 1 | 2017 | 12 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2017 | 15 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2022 | 1748 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 71 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 1862 | 0.030 |
Why?
|
| Risk Factors | 1 | 2021 | 1475 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 73 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 19 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 181 | 0.030 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2014 | 4 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2014 | 4 | 0.030 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2014 | 7 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 22 | 0.030 |
Why?
|
| Binding Sites | 1 | 2014 | 43 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2012 | 14 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 2018 | 1324 | 0.020 |
Why?
|